Promyelocytic leukemia (PML) nuclear bodies are disorganized in colorectal tumors with total loss of major histocompatibility complex class I expression and LMP7 downregulation

Tissue Antigens

Volumn 63, Issue 5, 2004, Pages 446-452

  Cabrera, C M ^a   Jimenez P ^a   Concha, A ^a   Garrido, F ^a   Ruiz Cabello, F ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Colorectal tumors; HLA; LMP7; PML

Indexed keywords

HLA ANTIGEN CLASS 1; KI 67 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROMYELOCYTIC LEUKEMIA PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CELL NUCLEUS INCLUSION BODY; COLORECTAL TUMOR; DOWN REGULATION; GENE DISRUPTION; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY COMPLEX; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION;

COLORECTAL NEOPLASMS; DOWN-REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; MULTIENZYME COMPLEXES; NEOPLASM PROTEINS; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 2442568547     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0001-2815.2004.00204.x     Document Type: Article

References (30)

1. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15:17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991: 66: 675-84.
2. Goddard AD, Borrow J, Freemont PS, Solomon E. Characterization of a zinc finger gene disrupted by the t(15:17) in acute promyelocytic leukemia. Science 1991: 254: 1371-4.
3. Hodges M, Tissot C, Howe K, Grimwade D, Freemont PS. Structure, organization and dynamics of promyelocytic leukemia protein nuclear bodies. Am J Hum Genet 1998: 63: 297-304.
4. Seeler JS, Dejean A. The PML nuclear bodies: actors or extras? Curr Opin Genet Dev 1999: 9: 362-7.
5. Zhong S, Hu P, Ye TZ, Stan R, Ellis NA, Pandolfi PP. A role for PML and the nuclear body in genomic stability. Oncogene 1999: 18: 7941-7.
6. Zhong S, Salomoni P, Ronchetti S, Guo A, Ruggero D, Pandolfi PP. Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis. J Exp Med 2000: 191: 631-40.
7. Anton LC, Schubert U, Bacik I, Princiotta MF, Wearsch PA, Gibbs J et al. Intracellular localization of proteasomal degradation of a viral antigen. J Cell Biol 1999: 1: 113-24.
8. Mattsson K, Pokrovskaja K, Kiss C, Klein G, Szekely L. Proteins associated with the promyelocytic leukemia gene product (PML)-containing nuclear body move to the nucleolus upon inhibition of proteasome-dependent protein degradation. Proc Natl Acad Sci USA 2001: 98: 1012-7.
9. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998: 17: 7151-60.
10. Saitoh H, Pu RT, Dasso M. SUMO-1: wrestling with a new ubiquitin-related modifier. Trends Biochem Sci 1997: 22: 374-6.
11. Zhu J, Lallemand-Breitenbachn V, de The H. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARα catabolism, role of oncogene degradation in disease remission. Oncogene 2001: 20: 7257-65.
12. Lamond AI, Earnshaw WC. Structure and function in the nucleus. Science 1998: 280: 547-53.
13. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today 1997: 18: 89-95.
14. Pawelec G, Zeuthen J, Kiessling R. Escape from host-antitumor immunity. Crit Rev Oncog 1997: 8: 111-41.
15. Johnsen A, France J, Sy MS, Harding CV. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. Cancer Res 1998: 58: 3660-7.
16. Rivoltini L, Barracchini DC, Viggiano V, Kawakami Y, Smith A, Mixon A et al. Quantitative correlation between HLA class I expression and recognition of melanoma cells by antigen specific cytotaric T lymphocytes. Cancer Res 1995: 55: 3149-57.
17. 2-microglobulin motivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens 2003: 61: 211-9.
18. Cabrera T, Fernández MA, Sierra A, Garrido A, Herruzo A, Escobedo A et al. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 1996: 50: 127-34.
19. Jiménez P, Cantón J, Collado A, Cabrera T, Serrano A, Real LM et al. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer 1999: 83: 91-7.
20. Cabrera T, Collado A, Fernández MA, Ferron A, Sancho J, Ruit-Cabello F et al. High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens 1998: 52: 114-23.
21. Ramal LM, Maleno I, Cabrera T, Collado A, Ferron A, López-Nevot MA et al. Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Hum Immunol 2000: 61: 1001-12.
22. Regad T, Mounira CA. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 2001: 20: 7274-86.
23. Zheng P, Guo Y, Niu Q, Levy DE, Dyck JA, Lu S et al. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature 1998: 396: 373-6.
24. Chang SK, Park B, Shin J, Ahn JH, Kim IH, Ahn K. Proto-oncogene PML enhances antigen presentation by MHC class I molecules in human lung cancer cells. Mol Cells 2002: 31: 130-5.
25. Shiels C, Islam SA, Vatcheva R, Sasieni P, Sternberg MJE, Freemont PA et al. PML bodies associate specifically with the MHC gene cluster in interphase nuclei. J Cell Sci 2001: 114: 3705-16.
26. Larghero J, Zassadowski F, Rousselot P, Padua RA, Degos L, Chomienne C. Alteration of the PML proto-oncogene in leukemic cells does not abrogate expression of MHC class I antigens. Leukemia 1999: 13: 1295-6.
27. Ruggero D, Wang ZG, Pandolfi PP. The puzzling multiple lives of PML and its role in the genesis of cancer. Bioessays 2000: 22: 827-35.
28. Fabunmi RP, Wigley C, Thomas PJ, DeMartino GN. Interferon γ regulates accumulation of the proteasome activator PA28 and immune proteasome at nuclear PML bodies. J Cell Sci 2000: 114: 29-36.
29. - mice. Science 1999: 286: 2162-5.
30. Fehling HJ, Swat W, Laplace C, Kühn R, Rajewsky K, Müller U et al. MHC dass I expression in mice lacking the proteasome subunit LMP7. Science 1994: 265: 1234-7.